29 June 2012
Repeated graft loss after orthotopic liver transplantation: A case report
Oskar KornasiewiczACDEF, Karol ZbrońskiABCE, Michał GrątABC, Krzysztof ZieniewiczD, Marek KawczykAGDOI: 10.12659/AOT.883232
Ann Transplant 2012; 17(2): 131-134
Abstract
Background: Multiple orthotopic liver transplantations (OLTx), although relatively uncommon, are the only known therapy for repeated graft failure. Moreover, re-transplantation (re-OLTx) of more than 2 grafts is sparsely reported thus far.
Case Report: We describe here 2 cases of patients who fulfilled the criteria for undergoing more than 2 OLTx. Each patient received 3 grafts in total. The primary early indication for the first re-OLTx in both cases was hepatic artery thrombosis (HAT). Prior to the second re-OLTx, both patients were in poor general condition. In 1 case, the second graft failed due to the recurrence of primary sclerosing cholangitis; the patient was re-transplanted electively 69 months after the primary re-OLTx. In the other case, the patient required a non-elective second re-OLTx within 1 month after the first re-OLTx due to primary graft failure. In both patients, the second and the third re-OLTs were performed using a veno-venous bypass with hepaticojejunostomy on an already existing Roux-en-Y loop. While 1 patient died postoperatively due to multi-organ failure, the other is alive with good synthetic liver function at 60 months after the last transplantation. The overall mortality rate of this procedure was thus 50%.
Conclusions: Although repeated OLT of more than 2 grafts is technically feasible and in selected patients can be a life-saving procedure, it is rarely performed. In our limited experience, it is burdened with relatively high mortality and morbidity, unspecified indications regarding patient selection, and competition between patients awaiting liver transplantation.
Keywords: hepatic artery thrombosis, re-transplantation, primary nonfunction
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






